AAM's Francer Talks Quality, Pricing And Biosimilars
Following Appearance At The India Pharmaceutical Forum
Executive Summary
Association for Accessible Medicines interim CEO and general counsel Jeff Francer, in an interview with Generics Bulletin sister publication Scrip, discusses the industry body’s continued efforts to ensure that generics and biosimilars are not disadvantaged in the US by the brand name industry's commercial tactics or legal/regulatory moves, and outlines the 'enormous progress' made by generic firms on quality.
You may also be interested in...
India Pharma Forum: What The FDA, Indian Regulator Flagged Up
The two-day India Pharmaceutical Forum in Mumbai highlighted key aspects of quality management and its challenges, trends on inspection outcomes in India and emerging concerns of 'dangerous cross contamination.'
The Failure Of Biosimilars In The US: ‘Headline’ News
A Washington Post article on price hikes for Abbvie’s Humira highlights patent ‘thickets’ and anti-biosimilar strategies. But the lack of understanding of the basic concepts of the biosimilar system are a much bigger warning sign about the viability of the pathway.
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: